Nicole Williams, MD | Authors

VALLEY LONG TERM PHARMACY

123 E GARDINER ST # 12

Articles

Triple-Negative Breast Cancer in the Post-Genomic Era

September 15, 2013

Clearly there is no single therapy for all patients with TNBC, given the molecular heterogeneity of this subtype. However, new insights from further genomic analysis of TNBC suggest approaches to rational clinical trial design, and patients will undoubtedly benefit as we define the most appropriate therapeutic targets in management of this aggressive disease.